NCT01259336

Efficacy Of Itraconazole In Chronic Cavitary Pulmonary Aspergillosis

A RANDOMIZED CONTROLLED STUDY OF ITRACONAZOLE IN CHRONIC CAVITARY PULMONARY ASPERGILLOSIS

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 31 (actual)
• Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh · Academic / Other
• Sex: All
• Age: 14 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether there itraconazole is effective in the treatment of chronic cavitary pulmonary aspergillosis

Detailed description

The role of itraconazole is still not clear in the treatment of chronic cavitary pulmonary aspergillosis(CCPA). Some studies have shown a beneficial role of itraconazole in reducing hemoptysis. So the present study is aimed at analyzing the role of itraconazole in CCPA.

Conditions

• Chronic Cavitary Pulmonary Aspergillosis

Interventions

Type	Name	Description
DRUG	Itraconazole	Tablet 200 mg twice daily for 6 months
DRUG	treatment in cavitary pulmonary aspergillosis	Anti-tussive, blood transfusion, surgical resection and bronchial artery embolisation(BAE)

Timeline

• Start date: 2010-07-01
• Primary completion: 2011-06-01
• Completion: 2011-12-01
• First posted: 2010-12-14
• Last updated: 2012-02-22

Locations

1 site across 1 country: India